BioSpace News Archive

InflaRx N.V., a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced the pricing of its underwritten public offering of 9,411,765 ordinary shares at an offering price of $4.25 per ordinary share.

Shanghai Junshi Biosciences Co., Ltd announced that a randomized, double-blind, placebo-controlled, multi-center phase III clinical study investigating the poly polymerase inhibitor, senaparib, had finished its pre-specified interim analysis.

INVO Bioscience, Inc. will report financial results for its fourth quarter and fiscal year 2022, for the period ended December 31, 2022, after the market close on Monday, April 17, 2023.

Ocugen, Inc., a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, announced that it will host an Investor and Analyst Event on April 14, 2023, at 8 a.m. ET.

HUTCHMED Limited announces that new and updated clinical and non-clinical data related to five HUTCHMED investigational drug candidates will be presented during the American Association for Cancer Research Annual Meeting 2023, which will take place from April 14 to 19, 2023 in Orlando, Florida.

Araris Biotech AG announced that Samsung Venture Investment Corporation, an investment corporation established to promote the development of new technologies, has invested in the Company in an independent deal ahead of its on-going series A funding.

GC Genome Corporation, a leading genomic diagnostics company, announced the publication of a new study in Nature Communications, showcasing the company’s novel AI-based liquid biopsy technology.

Systech, part of Markem-Imaje and Dover, a leading provider of digital identification and traceability software solutions, announced a series of services designed to help customers in the pharmaceutical supply chain meet Drug Supply Chain Security Act interoperability requirements by the November 27 deadline.

AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the 2023 Bloom Burton & Co. Healthcare Investor Conference in Toronto on Tuesday, April 25, 2023, at 6:30 a.m. Pacific Time (9:30 a.m. Eastern Time).